Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 2/20 | 0.55 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | IAPP | P10997 | 3/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.42 |
| ▸ | YWHAG | P61981 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746070 | 0.88 | CYP4F2 (0.58) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL30291871 | 0.86 | APP (0.73) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL490911 | 0.86 | APP (0.73) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL4190020 | 0.84 | APP (0.50) | APPIAPPPTPN1 | |
| SCHEMBL16319014 | 0.84 | CYP4F2 (0.61) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL12984627 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11APPCYP4Z1PDE3B | |
| SCHEMBL31511763 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11APPCYP4Z1PDE3B | |
| SCHEMBL17295176 | 0.82 | CYP4F2 (0.55) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL9925913 | 0.82 | CYP4F2 (0.58) | CYP4F2CYP4A11APPCYP4Z1IAPP | |
| SCHEMBL5274836 | 0.82 | CYP4F2 (0.58) | CYP4F2CYP4A11APPCYP4Z1IAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227914-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227914-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227914-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150183723-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2015-07-02 | — | — | US | disclosed |
| US-20150183723-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2015-07-02 | — | — | US | disclosed |
| US-20150183723-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2015-07-02 | — | — | US | disclosed |
| US-8980950-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980950-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980950-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140057980-A1 | CALCILYTIC COMPOUNDS | GlaxoSmithKline, LLC (US) | 2014-02-27 | — | — | US | disclosed |
| US-7829594-B2 | calcium receptor antagonists such as 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxyl]-phenyl}-propionic acid, used to increase serum parathyroid hormone levels in mammals | GlaxoSmithKline, LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090163589-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM. CORP. | 2009-06-25 | — | — | US | disclosed |
| US-20090163589-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM. CORP. | 2009-06-25 | — | — | US | disclosed |
| US-20090163589-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM. CORP. | 2009-06-25 | — | — | US | disclosed |
| US-7514473-B2 | Calcilytic compounds | SMITHKLINE BEECHAM, CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514473-B2 | Calcilytic compounds | SMITHKLINE BEECHAM, CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514473-B2 | Calcilytic compounds | SMITHKLINE BEECHAM, CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20060058391-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1569892-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004047751-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163589-A1 | Calcilytic Compounds | SOST, CALCB, CALCR | CYP4F2 2478/4885CYP4A11 3734/4885APP 1632/4885 |
| US-20060058391-A1 | Calcilytic compounds | SOST, CALCB, CALCR | CYP4F2 2478/4885CYP4A11 3736/4885APP 1632/4885 |
| US-20150183723-A1 | Calcilytic Compounds | SOST, CALCB, CALCR | CYP4F2 2478/4885CYP4A11 3736/4885APP 1632/4885 |
| US-20140057980-A1 | CALCILYTIC COMPOUNDS | SOST, CALCB, CALCR | CYP4F2 2478/4885CYP4A11 3736/4885APP 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.